WO1995015746A1
(en)
*
|
1993-12-10 |
1995-06-15 |
The School Of Pharmacy |
Liposome delivery systems
|
US5931809A
(en)
*
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
DE69739319D1
(de)
|
1996-12-13 |
2009-04-30 |
Novartis Vaccines & Diagnostic |
Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe
|
US6511477B2
(en)
*
|
1997-03-13 |
2003-01-28 |
Biocardia, Inc. |
Method of drug delivery to interstitial regions of the myocardium
|
US6443949B2
(en)
*
|
1997-03-13 |
2002-09-03 |
Biocardia, Inc. |
Method of drug delivery to interstitial regions of the myocardium
|
IL135060A
(en)
|
1997-09-18 |
2005-12-18 |
Skyepharma Inc |
Sustained release liposomal anesthetic compositions and methods for the preparation thereof
|
WO1999024578A2
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
WO1999025319A1
(en)
|
1997-11-14 |
1999-05-27 |
Depotech Corporation |
Production of multivesicular liposomes
|
CA2317815A1
(en)
|
1998-01-14 |
1999-07-22 |
Chiron S.P.A. |
Neisseria meningitidis antigens
|
WO2001031019A2
(en)
|
1999-10-29 |
2001-05-03 |
Chiron Spa |
Neisserial antigenic peptides
|
EP2261339B1
(en)
|
1998-05-01 |
2017-03-22 |
GlaxoSmithKline Biologicals SA |
Neisseria meningitidis antigens and compositions
|
US6740643B2
(en)
*
|
1999-01-21 |
2004-05-25 |
Mirus Corporation |
Compositions and methods for drug delivery using amphiphile binding molecules
|
NZ513829A
(en)
*
|
1999-03-02 |
2001-09-28 |
Liposome Co Inc |
Encapsulation of bioactive complexes in liposomes
|
NZ571167A
(en)
|
1999-04-30 |
2010-05-28 |
Novartis Vaccines & Diagnostic |
Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
AUPQ259399A0
(en)
|
1999-09-01 |
1999-09-23 |
Lustre Investments Pte Ltd |
Therapeutic agents
|
EP2163626A1
(en)
|
1999-11-18 |
2010-03-17 |
Novartis Vaccines and Diagnostics, Inc. |
Human FGF-21 gene and gene expression products
|
US20070219363A1
(en)
*
|
1999-11-29 |
2007-09-20 |
Budker Vladimir G |
Chelating Compound for Drug Delivery
|
CN1434706A
(zh)
|
1999-12-23 |
2003-08-06 |
神经化学公司 |
用于调节脑淀粉状蛋白性血管病的化合物和方法
|
PT1248647E
(pt)
|
2000-01-17 |
2010-11-18 |
Novartis Vaccines & Diagnostics Srl |
Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
|
AU2001249125A1
(en)
|
2000-03-08 |
2001-09-17 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
US20060141455A1
(en)
|
2002-01-08 |
2006-06-29 |
Rhonda Hansen |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
DE60134275D1
(de)
|
2000-06-15 |
2008-07-10 |
Novartis Vaccines & Diagnostic |
Polynukleotide zur bestimmung von kolonkrebs
|
EP2277894A1
(en)
|
2000-10-27 |
2011-01-26 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic acids and proteins from streptococcus groups A & B
|
US20020160991A1
(en)
*
|
2000-12-04 |
2002-10-31 |
Liming Shao |
Orally-bioavailable formulations of fentanyl and congeners thereof
|
EP1415005B1
(en)
|
2000-12-07 |
2012-11-21 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
BR0102252B1
(pt)
*
|
2001-04-10 |
2013-10-22 |
|
Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
|
KR20030022094A
(ko)
|
2001-05-24 |
2003-03-15 |
(주)휴먼디엔에이테크놀로지 |
모낭에 존재하는 새로운 제 2 케라티노사이트 성장인자유사체
|
FR2827516B1
(fr)
*
|
2001-07-19 |
2003-09-19 |
Servier Lab |
Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
|
BRPI0105509B8
(pt)
*
|
2001-11-05 |
2021-05-25 |
Univ Minas Gerais |
formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
|
WO2003039491A2
(en)
|
2001-11-09 |
2003-05-15 |
Georgetown University |
Novel isoforms of vascular endothelial cell growth inhibitor
|
JP4413617B2
(ja)
|
2001-12-12 |
2010-02-10 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Chlamydiatrachomatisに対する免疫化
|
AU2003218350A1
(en)
|
2002-03-21 |
2003-10-08 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
AU2003276679A1
(en)
|
2002-06-13 |
2003-12-31 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
EP1543841A4
(en)
*
|
2002-08-15 |
2011-03-16 |
Yunqing Liu |
SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
PL215171B1
(pl)
|
2002-12-24 |
2013-10-31 |
Rinat Neuroscience Corp |
Przeciwcialo przeciw czynnikowi wzrostu nerwów (NGF) lub jego fragment, kompozycja farmaceutyczna, zestaw, sposób wytwarzania przeciwciala lub jego fragmentu, zastosowanie skutecznej ilosci antagonistycznego przeciwciala anty-NGF lub jego fragmentu, zastosowanie antagonistycznego przeciwciala anty-NGF lub jego fragmentu, izolowany polinukleotyd zawierajacy sekwencje nukleotydowa kodujaca przeciwcialo lub jego fragment, wektor oraz komórka gospodarza zawierajaca polinukleotyd
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
AU2004213452A1
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic GPCR targets in cancer
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
BRPI0407375A
(pt)
|
2003-02-19 |
2006-02-07 |
Rinat Neuroscience Corp |
Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
ES2426915T3
(es)
|
2003-09-10 |
2013-10-25 |
Brentwood Equities Ltd. |
Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
|
EA200601220A1
(ru)
|
2003-12-23 |
2006-12-29 |
Ринат Ньюросайенс Корп. |
Анти-trkc антитела-агонисты и способы их применения
|
CN1957082B
(zh)
|
2004-03-29 |
2014-09-17 |
株式会社嘉尔药物 |
新的半乳凝素9突变体蛋白质及其用途
|
CA2562024C
(en)
|
2004-04-07 |
2014-05-27 |
Rinat Neuroscience Corp. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
KR100896697B1
(ko)
|
2004-04-09 |
2009-05-14 |
(주)아모레퍼시픽 |
고압유화기술에 의한 대황추출물의 경피흡수 촉진방법 및이를 응용한 미백용 피부 외용제 조성물
|
US8865171B2
(en)
|
2004-07-09 |
2014-10-21 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus G glycoprotein
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
EP2298807A3
(en)
|
2004-07-30 |
2011-05-18 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
WO2006026713A2
(en)
*
|
2004-08-31 |
2006-03-09 |
Tracie Martyn International, Llc |
Topical benfotiamine and pyridoxamine compositions
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
NZ560929A
(en)
|
2005-02-18 |
2009-12-24 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
EP1910557A2
(en)
|
2005-04-07 |
2008-04-16 |
Chiron Corporation |
Cancer-related genes
|
US20070014845A1
(en)
*
|
2005-07-01 |
2007-01-18 |
Yuanpeng Zhang |
Liposomal delivery vehicle for hydrophobic drugs
|
BRPI0613770A2
(pt)
|
2005-07-22 |
2009-05-19 |
Y S Therapeutics Co Ltd |
anticorpos anti-cd26 e métodos de uso destes
|
US8591457B2
(en)
|
2005-08-10 |
2013-11-26 |
Alza Corporation |
Method for making a needle-free jet injection drug delivery device
|
EP3069731A1
(en)
|
2005-11-14 |
2016-09-21 |
Labrys Biologics Inc. |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
US7658913B2
(en)
*
|
2005-11-28 |
2010-02-09 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
US20070123478A1
(en)
*
|
2005-11-28 |
2007-05-31 |
Rowe Vernon D |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
KR100793824B1
(ko)
|
2006-03-06 |
2008-01-11 |
(주)아모레퍼시픽 |
하이드록시프로필-베타사이클로 덱스트린을 이용하여가용화된 유용성 생리활성성분을 담지하는 고분자-리포좀나노복합체
|
JP2009525319A
(ja)
*
|
2006-02-02 |
2009-07-09 |
ライナット ニューロサイエンス コーポレイション |
trkBアンタゴニストを投与することにより肥満を治療する方法
|
TW200808352A
(en)
*
|
2006-02-02 |
2008-02-16 |
Rinat Neuroscience Corp |
Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist
|
NZ572561A
(en)
|
2006-06-07 |
2012-05-25 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
WO2008124176A2
(en)
|
2007-04-10 |
2008-10-16 |
The Administrators Of The Tulane Educational Fund |
Soluble and membrane-anchored forms of lassa virus subunit proteins
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
CA2709135C
(en)
|
2007-12-17 |
2018-06-05 |
Pfizer Limited |
Treatment of interstitial cystitis
|
KR101672271B1
(ko)
|
2007-12-18 |
2016-11-03 |
바이오얼라이언스 씨.브이. |
암세포에서 발현된 cd-43 및 cea 상의 탄수화물 함유 에피토프를 인식하는 항체 및 그것의 사용 방법
|
US20090196917A1
(en)
*
|
2008-02-01 |
2009-08-06 |
University Of Kentucky Research Foundation |
Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
|
CA2718975A1
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
ES2464729T3
(es)
|
2008-08-21 |
2014-06-03 |
The Johns Hopkins University |
Procedimientos y composiciones para la administración de 3-halopiruvato y compuestos relacionados para el tratamiento del cáncer
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
CA2742988A1
(en)
*
|
2008-11-17 |
2010-05-20 |
Genentech, Inc. |
Method and formulation for reducing aggregation of a macromolecule under physiological conditions
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
CA2754618A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
WO2010113983A1
(ja)
*
|
2009-03-30 |
2010-10-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
リポソーム組成物の製造方法
|
TWI392519B
(zh)
|
2009-03-30 |
2013-04-11 |
Eisai R&D Man Co Ltd |
Liposomal composition
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
CA2763365C
(en)
|
2009-05-29 |
2016-09-13 |
Cydex Pharmaceuticals, Inc. |
Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
SI2464658T1
(sl)
|
2009-07-16 |
2015-02-27 |
Novartis Ag |
Detoksificirani imunogeni escherichie coli
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
TWI596114B
(zh)
|
2010-02-24 |
2017-08-21 |
雷那特神經科學股份有限公司 |
拮抗劑抗-il-7受體抗體及方法
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
SG10201507722QA
(en)
|
2010-03-11 |
2015-10-29 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US9993793B2
(en)
|
2010-04-28 |
2018-06-12 |
The Procter & Gamble Company |
Delivery particles
|
US9186642B2
(en)
|
2010-04-28 |
2015-11-17 |
The Procter & Gamble Company |
Delivery particle
|
US9770414B2
(en)
*
|
2010-05-13 |
2017-09-26 |
Pacira Pharmaceuticals, Inc. |
Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
|
JP2013533286A
(ja)
|
2010-07-30 |
2013-08-22 |
セントルイス ユニバーシティ |
疼痛を治療する方法
|
CN103260702B
(zh)
*
|
2010-10-28 |
2018-07-27 |
帕西拉制药有限公司 |
非甾体类抗炎药的缓释制剂
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
WO2012118796A1
(en)
|
2011-02-28 |
2012-09-07 |
The Schepens Eye Research Institute, Inc. |
Compositions for controlling neuronal outgrowth
|
EP2694017B1
(en)
|
2011-04-07 |
2019-05-22 |
The Procter and Gamble Company |
Personal cleansing compositions with increased deposition of polyacrylate microcapsules
|
WO2012138696A2
(en)
|
2011-04-07 |
2012-10-11 |
The Procter & Gamble Company |
Shampoo compositions with increased deposition of polyacrylate microcapsules
|
MX2013010981A
(es)
|
2011-04-07 |
2013-10-30 |
Procter & Gamble |
Composiciones acondicionadoras con deposito mejorado de microcapsulas de poliacrilato.
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
CA2954166A1
(en)
|
2011-11-11 |
2013-05-16 |
Rinat Neuroscience Corp. |
Antibodies specific for trop-2 and their uses
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
MX2014007644A
(es)
|
2011-12-22 |
2014-09-26 |
Rinat Neuroscience Corp |
Anticuerpos antagonistas del receptor de hormona de crecimiento humana y metodos para su uso.
|
CN104427976B
(zh)
|
2012-05-10 |
2018-04-24 |
佩因拉佛姆有限公司 |
疏水的活性成分的储库制剂及其制备方法
|
EP2864360B1
(en)
|
2012-06-25 |
2017-09-06 |
The Brigham and Women's Hospital, Inc. |
Targeted therapeutics
|
WO2014008263A2
(en)
|
2012-07-02 |
2014-01-09 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Paramyxovirus and methods of use
|
MX363455B
(es)
*
|
2012-07-18 |
2019-03-25 |
Onyx Therapeutics Inc |
Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
CN105026426A
(zh)
|
2012-11-09 |
2015-11-04 |
辉瑞公司 |
血小板衍生生长因子b之特异性抗体及其组合物和用途
|
US11084860B2
(en)
|
2013-03-12 |
2021-08-10 |
The General Hospital Corporation |
Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
|
EP3594244A1
(en)
|
2013-03-15 |
2020-01-15 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
AU2014264295A1
(en)
|
2013-05-07 |
2015-10-29 |
Rinat Neuroscience Corp. |
Anti-glucagon receptor antibodies and methods of use thereof
|
TWM473835U
(zh)
*
|
2013-05-15 |
2014-03-11 |
Wu xu sheng |
微米牛樟芝微脂載體結構
|
US20170172922A1
(en)
*
|
2013-05-15 |
2017-06-22 |
Hsu-Shen WU |
Micron taiwanofungus camphoratus liposome structure
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
KR101809072B1
(ko)
|
2013-08-02 |
2017-12-14 |
화이자 인코포레이티드 |
항-cxcr4 항체 및 항체-약물 접합체
|
JP6740126B2
(ja)
|
2013-11-13 |
2020-08-12 |
ファイザー・インコーポレイテッド |
腫瘍壊死因子様リガンド1a特異的抗体ならびにその組成物および使用
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
CA2933335A1
(en)
|
2013-12-11 |
2015-06-18 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
|
CN106659683A
(zh)
*
|
2014-01-14 |
2017-05-10 |
约翰斯·霍普金斯大学 |
包封修饰的环糊精复合物的脂质体组合物及其应用
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
FI3119431T3
(fi)
|
2014-03-21 |
2024-03-20 |
Teva Pharmaceuticals Int Gmbh |
Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
WO2016166629A1
(en)
|
2015-04-13 |
2016-10-20 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
TWM513697U
(zh)
*
|
2015-06-26 |
2015-12-11 |
Ma Shen Kai Ruei Co Ltd |
仿生物間質系統的載體結構
|
US10877045B2
(en)
|
2015-07-21 |
2020-12-29 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
EA201890340A1
(ru)
|
2015-07-21 |
2018-09-28 |
Дайэкс Корп. |
Моноклональное антитело-ингибитор фактора xiia
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
CN107922506B
(zh)
|
2015-08-19 |
2021-11-09 |
辉瑞公司 |
组织因子途径抑制剂抗体及其用途
|
SI3350220T1
(sl)
|
2015-09-15 |
2021-12-31 |
Scholar Rock, Inc. |
Protitelesa proti pro/latentnemu miostatinu in uporabe le-teh
|
TW201722989A
(zh)
|
2015-10-23 |
2017-07-01 |
輝瑞大藥廠 |
抗il-2抗體及其組合物及用途
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
WO2017079563A1
(en)
|
2015-11-06 |
2017-05-11 |
The Johns Hopkins University |
Methods of treating liver fibrosis by administering 3-bromopyruvate
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
RU2744860C2
(ru)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Антитела и их конъюгаты
|
IL299759A
(en)
|
2015-12-30 |
2023-03-01 |
Genentech Inc |
Formulations with reduced polysorbate dissolution
|
JP2019506398A
(ja)
|
2016-01-21 |
2019-03-07 |
ファイザー・インク |
上皮増殖因子受容体変異体iiiおよびcd3の単一および二重特異性抗体およびそれらの使用
|
WO2018094253A1
(en)
|
2016-11-18 |
2018-05-24 |
Pacira Pharmaceuticals, Inc. |
Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
|
US11198735B2
(en)
|
2017-03-03 |
2021-12-14 |
Rinat Neuroscience Corp. |
Anti-GITR antibodies and methods of use thereof
|
US20200056190A1
(en)
|
2017-03-16 |
2020-02-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
KR102505349B1
(ko)
|
2017-06-02 |
2023-03-02 |
화이자 인코포레이티드 |
Flt3에 특이적인 항체 및 이의 용도
|
AU2018284077B2
(en)
|
2017-06-13 |
2021-09-23 |
Bostongene Corporation |
Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
AU2018344859A1
(en)
|
2017-10-04 |
2020-04-30 |
Hesperix SA |
Articles and methods directed to personalized therapy of cancer
|
EP3706801A4
(en)
*
|
2017-11-08 |
2022-04-06 |
L.E.A.F Holdings Group LLC |
PLATINUM COMPLEXES AND THEIR USES
|
AU2019215075A1
(en)
|
2018-02-01 |
2020-08-20 |
Pfizer Inc. |
Antibodies specific for CD70 and their uses
|
PE20211299A1
(es)
|
2018-02-01 |
2021-07-20 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70
|
JP2021516045A
(ja)
|
2018-02-28 |
2021-07-01 |
ファイザー・インク |
Il−15バリアントおよびその使用
|
US11525010B2
(en)
|
2018-05-23 |
2022-12-13 |
Pfizer Inc. |
Antibodies specific for GUCY2c and uses thereof
|
WO2019224715A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
MX2021001820A
(es)
*
|
2018-09-14 |
2021-04-28 |
Pharmosa Biopharm Inc |
Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.
|
EP3906263A4
(en)
|
2019-01-03 |
2022-08-31 |
Underdog Pharmaceuticals, Inc. |
CYCLODEXTRIN DIMERS, THEIR COMPOSITIONS AND USES
|
CA3146077A1
(en)
|
2019-07-03 |
2021-02-18 |
Bostongene Corporation |
Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
CA3153932A1
(en)
|
2019-10-07 |
2021-04-15 |
Jonathan Kipnis |
Modulating lymphatic vessels in neurological disease
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
WO2021151079A1
(en)
|
2020-01-24 |
2021-07-29 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
EP4189093A1
(en)
|
2020-07-30 |
2023-06-07 |
Pfizer Inc. |
Cells having gene duplications and uses thereof
|
CA3190513A1
(en)
|
2020-09-03 |
2022-03-10 |
Jeffrey S. Bartlett |
Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
|
CN112190498B
(zh)
*
|
2020-10-31 |
2022-03-25 |
华南理工大学 |
一种具有水溶性的茶碱和环糊精包合物及其制备方法
|
US20220180972A1
(en)
|
2020-12-04 |
2022-06-09 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
WO2022232615A1
(en)
|
2021-04-29 |
2022-11-03 |
Bostongene Corporation |
Machine learning techniques for estimating tumor cell expression complex tumor tissue
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
WO2023147177A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
US20240029884A1
(en)
|
2022-07-15 |
2024-01-25 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|